Evidence map›Paper›PMID 37246850›Full record

SynthesisAnnals of medicine2023

Gut microbiota-derived trimethylamine N-oxide is associated with the risk of all-cause and cardiovascular mortality in patients with chronic kidney disease: a systematic review and dose-response meta-analysis.

Yachun Li, Hongmei Lu, Jing Guo, Meiling Zhang, Huijuan Zheng, Yuning Liu, Weijing Liu

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Annals of medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 3 pooled it
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 3 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Trimethylamine-N-oxide: the microbial cue in immune-mediated disorders.Trends in endocrinology and metabolism: TEM · 2026
    Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yachun LiDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, P.R. China.
Hongmei LuDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, P.R. China.
Jing GuoDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, P.R. China.ORCID 0000-0002-4781-8200
Meiling ZhangDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, P.R. China.
Huijuan ZhengDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, P.R. China.ORCID 0000-0002-8394-0844
Yuning LiuDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, P.R. China.
Weijing LiuDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, P.R. China.ORCID 0000-0002-5356-7057
Ministry of Education of the People's Republic of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTrimethylamine N-oxide (TMAO) derived from gut microbiota causes kidney-heart damage in chronic kidney disease (CKD) patients. However, it is controversial whether CKD patients with higher TMAO are associated with a higher risk of death. We aimed to assess the correlation between circulating TMAO concentration and the risk of all-cause and cardiovascular death in CKD patients of different dialysis statuses and different races by dose-response analyses, and the underlying mechanisms were also explored by analyzing the correlations of TMAO with glomerular filtration rate (GFR) and inflammation.

methodPubMed, Web of Science, and EMBASE were systematically searched up to 1 July 2022. A total of 21 studies involving 15,637 individuals were included. Stata 15.0 was used to perform the meta-analyses and dose-response analyses with extracted data. Subgroup analyses were conducted to recognize possible sources of heterogeneity.

resultsThe risk of all-cause mortality was increased in non-dialysis CKD patients (RR = 1.26, 95%CI = 1.03-1.54,

conclusionsIncreased circulating TMAO concentrations increase the risk of all-cause mortality in non-dialysis and non-black dialysis CKD patients. Moreover, elevated TMAO levels raise the cardiovascular mortality risk in non-black dialysis patients.Key messagesNon-dialysis and non-black dialysis CKD patients with higher circulating TMAO concentrations are associated with an increased risk of all-cause mortality.Non-black dialysis patients with higher concentrations of TMAO are associated with an increased risk of cardiovascular mortality.Circulating TMAO concentrations have a strong negative correlation with GFR and a positive correlation with inflammation biomarkers in non-dialysis CKD patients.

Indexed as

Cardiovascular DiseasesGastrointestinal MicrobiomeRenal Insufficiency, ChronicHumansInflammationMethylaminesMethylaminestrimethyloxamineall-cause mortalitycardiovascular mortalitychronic kidney diseaseTrimethylamine N-oxide

Identifiers

PMID37246850
PMCPMC10228303
OpenAlexW4378640247

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.